| Identification | Back Directory | [Name]
JNJ-7706621 | [CAS]
443797-96-4 | [Synonyms]
CS-409
JNJ-7706621 USP/EP/BP
JNJ7706621; JNJ 7706621
Aurora Kinase/Cdk Inhibitor
Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem
4-[[5-Amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide
Benzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-
4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide JNJ7706621 | [Molecular Formula]
C15H12F2N6O3S | [MDL Number]
MFCD11100270 | [MOL File]
443797-96-4.mol | [Molecular Weight]
394.36 |
| Chemical Properties | Back Directory | [Melting point ]
149-155℃ | [Boiling point ]
676.6±65.0 °C(Predicted) | [density ]
1.71 | [storage temp. ]
+2C to +8C | [solubility ]
Soluble in DMSO at 15mg/ml | [form ]
White solid | [pka]
9.80±0.12(Predicted) | [Sensitive ]
Light Sensitive |
| Hazard Information | Back Directory | [Description]
JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDKs) and Aurora kinases. It potently inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively).1 It shows selectivity for these enzymes over a panel of other receptors and kinases, although it exhibits submicromolar inhibition of VEGF and FGF receptors, as well as GSK3β.1 JNJ-7706621 blocks the growth of a large variety of cancer cell lines (IC50 values range from 112 to 514 nM), with lower potency against normal cells (IC50 values between 3.67 and 5.42 μM). It induces the regression of A375 melanoma human tumor xenografts in mice.1 JNJ-7706621 is a substrate for the ATP-binding cassette transporter G2, also known as breast cancer resistance protein.2 | [Uses]
JNJ-770662 is a broad spectrum inhibitor of cyclin-dependent kinases and aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B. JNJ-770662 has been shown to induce growth suppression and mitotic defects, these results suggest that JNJ-7706621 could be useful for cell cycle analysis and therapy of various cancers, including Ewing''s sarcoma. | [Definition]
ChEBI: 4-[[5-amino-1-[(2,6-difluorophenyl)-oxomethyl]-1,2,4-triazol-3-yl]amino]benzenesulfonamide is a sulfonamide. | [target]
CDK1 |
|
|